|| List of recent Mammal-related patents
|Organ regeneration method utilizing ips cell and blastocyst complementation|
It is revealed that an organ such as pancreas can be regenerated by utilizing a fact that the deficiency of an organ is complemented by injecting an induced pluripotent stem cell (ips cell) into a developed blastocyst in a blastocyst complementation method. Thus, the present invention has solved the above-described object.
|Medical assembly using short pulse fiber laser|
A method of ablating a solid substance within a mammalian body is presented. The method includes generating a superheated zone within the body using a fiber lasing assembly that emits pulses at a pulse repetition rate of 1 khz to 500 khz, where each pulse has a wavelength from 1.7 micron to 2.2 micron, a pulse width from 2 ns to 800 ns, and a pulse energy from 0.05 mj to 2 mj.
|Infusion set with quick connect, self-aligned electrical contacts|
A device and method for delivering a therapeutic substance to the body of a mammal are provided. The device includes a pump adapter, a pump, and an infusion set having a distal connector and a proximal connector.
|Optical sensor device and image processing unit for measuring chemical concentrations, chemical saturations and biophysical parameters|
Optical sensor devices, image processing devices, methods and computer readable code computer-readable storage media for detecting biophysical parameters, chemical concentrations, chemical saturations, vital signs and physiological information such as a malignant condition are provided. In some embodiments, the optical sensor includes an array of photodetectors, where each photodetector is configured to detect a spectrum of light.
|Methods and products for reawakening retrocyclins|
Products and methods are provided for the restoring the endogenous expression of theta-defensins, such as retrocyclin-1, in mamallian cells. The present invention also includes products and methods for inhibiting sexually transmitted virus entry, e.g., hiv-1 virus entry, into a mammalian cell via, for example, administering to a subject an amount of a read-through mediating agent sufficient to induce exogenous expression of an amount of retrocyclin nonapeptides in the mammalian cell..
|Combination analgesic employing opioid agonist and neutral antagonist|
In some embodiments, the invention provides a non-addictive analgesic co-formulation comprising an opioid agonist in an amount sufficient to confer analgesia in a mammalian subject (such as a human) and a neutral opioid antagonist in an amount sufficient to inhibit peripheral effects of the opioid agonist, and insufficient to block substantial central effects of the opioid agonist in the subject. The formulation may be formulated for oral administration to the subject.
|N-substituted indenoisoquinolines and syntheses thereof|
N-substituted indenoisoquinoline compounds, and pharmaceutical formulations of n-substituted indenoisoquinoline compounds are described. Also described are processes for preparing n-substituted indenoisoquinoline compounds.
|Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use|
Benzopyran and benzoxepin compounds of formulas i and ii, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of pi3k, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of formulas i and ii for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed..
|Novel galectoside inhibitors of galectins|
The present invention relates to novel compounds prepared from readily accessible 3-o-propargyl-d-galactopyranoside derivatives and having an effect as i.a., galectin inhibitors, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to ligands in a mammal, wherein said galectin is preferably a galectin-3. The novel compounds are defined by the general formula (i)..
|Mobile vessel or carrier for the manufacturing production and purification of biologics|
Embodiments described herein relate to mobile biologics production systems that can be transported to a site where a production of biologics is required, and is operable to produce the biologics on-site on demand. A mobile biologics production system can include a mobile carrier configured to be trailered to a biologics production location.
|Method and apparatus for detecting cancer in mammals|
The invention provides a method and apparatus for detecting cancer using the measurement of acute-phase proteins (apps) and the measurement of thymidine kinase activiy level in body fluids. An index is calculated based on the measured data and compared with a pre-established reference that allows a pratitioner to determine a high probabilty that a patient is a carrier of cancer..
|Method and system for identifying a biomarker indicative of health condition|
By designing a retrogression-progression model in combination with oral microbial community analysis, the present invention provides a method of identifying a biomarker indicative of a subject mammal's condition, wherein the condition is selected from presence of the first disease, severity of the first disease, sensitivity to the first disease, and combinations thereof. The present invention further provides a computer-aided system of identifying a biomarker indicative of a subject mammal's condition..
|Method of tumor screening|
A method for tumor screening using urine of a mammal, the method includes obtaining a total urine nucleic acid (e.g., dna) from a urine sample of a mammal, extracting a high molecular weight urine nucleic acid (above 1000 bp) by contacting the total urine nucleic acid with an adsorbent in the presence of a buffer which promotes binding of the high molecular weight urine nucleic acid to the adsorbent, replacing the buffer which promotes binding of the high molecular weight urine nucleic acid with a buffer which promotes binding of the low molecular weight urine nucleic acid to the adsorbent, extracting the low molecular weight urine nucleic acid by contacting with the adsorbent, eluting the low molecular weight urine nucleic acid, and assaying the low molecular weight urine nucleic acid for a presence or absence of a gene sequence specific to a certain type of tumor.. .
|Deep topical systemic nitric oxide therapy apparatus and method|
A topical mixture that produces nitric oxide and a method for using the topical mixture to increase the vasodilation of a bloodstream via transdermal absorption of the nitric oxide. The nitric oxide can then affect subcutaneous tissues.
|Controlled-release injectable microparticle|
The invention relates to a controlled-release injectable microparticle comprising a polyvinyl alcohol polymer and one or more hormones, in particular progesterone. Said microparticle induces estrus in female mammals after a single application.
|Regeneration aid for bone defects|
The invention relates to a molded part for supporting bone regeneration, in particular the regeneration of a jawbone or jawbone section in a mammal, preferably a human, wherein the molded part is suitable for applying to the jawbone and has a coating having a composition comprising at least one collagen, a granular material, and hyaluronic acid or a hyaluronic acid derivative. The invention further relates to a granular material that can be used in the coating, to a method for producing the granular material, and to the use of the molded part..
|Tissue scaffolds derived from forestomach extracellular matrix|
The present invention pertains to the development of extracellular matrix (ecm) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction.
|Adenoviral vector-based malaria vaccines|
The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a p.
|Anti-cd79b antibodies and immunoconjugates and methods of use|
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.. .
|Mammalian cytokines; related reagents and methods|
Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided..
|Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders|
Methods of treating or delaying onset of a neurodegenerative disorder with α-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble α-synuclein oligomer and capable of binding a stabilized soluble α-synuclein oligomer, the stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble α-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with α-synuclein pathology is characterized by deposition of lewy bodies and lewy neurites or is selected from the group consisting of parkinson's disease (pd), dementia with lewy bodies (dlb), the lewy body variant of alzheimer's disease, and multiple system atrophy (msa)..
|Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof|
The present invention relates to novel nanoparticles which can be advantageously used in the health sector as diagnostic and/or therapeutic agents. Nanoparticles of the invention comprise a metallic material at least partly covered with an hafnium oxide material or embedded therein.
|Methods and compositions for generating a mouse|
Methods of generating modified embryos and mammals by introduction of donor cells into an early stage embryo are provided, such that the resulting embryo and animal generated therefrom has a significant contribution to all tissues from the donor cells and is capable of transmitting the donor cell dna.. .
|Method, system, and apparatus for mammalian bony segment stabilization|
Embodiments of bony region stabilization are described generally herein. Other embodiments may be described and claimed..
|Implantable device with pivotable fastener and self-adjusting set screw|
An intramedullary device to repair a bone in a mammalian body and comprising an elongate nail having a stem and a head. The head is provided with a transverse aperture adapted to receive a fastener.
The present invention provides imidazotriazinone compounds which are inhibitors of phosphodiesterase 9. The present invention further provides processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of pde9 associated diseases or disorders in mammals, including humans..
|Small molecule inhibitors of stat3 with anti-tumor activity|
The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s31-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
|Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy|
The invention relates to methods and pharmaceutical compositions for treating hypertension and/or preventing or treating heart failure in a mammal receiving anti-coagulant therapy using compound(s) which are therapeutically effective but do not impact the pharmacokinetic or the pharmacodynamic effect(s) of the anti-coagulant, such as warfarin.. .
|Method of treating pain|
The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the trp channel may be trpc4.
|High dose buprenorphine compositions and use as analgesic|
The present disclosure relates to a method of providing prolonged analgesia to a mammal in need thereof. Specifically, the current disclosure is directed to a method of treating pain in a mammal for a prolonged period of time using a single high dose of a buprenorphine formulation..
|Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases|
The present invention provides a method for preferentially reducing the proliferation of cystic epithelial cells in the kidney or bile duct in a mammal in need thereof by administering a 20-hete synthesizing enzyme inhibitor or a 20-hete antagonist to the mammal in an amount sufficient to preferentially reduce the proliferation of cystic epithelial cells over normal epithelial cells such as tubule epithelial cells in the kidney or bile duct. The present invention also provides a method for preventing or treating autosomal dominant polycystic kidney disease (adpkd), autosomal recessive polycystic kidney disease (arpkd), arpkd associated congenital hepatic fibrosis, arpkd associated caroli's disease, or cholangiocarcinoma in a mammal in need thereof by administering a 20-hete synthesizing enzyme inhibitor or a 20-hete antagonist to the mammal in an amount sufficient to prevent or treat the disease..
|Inhibitor of colonisation of mucosa|
The present invention relates in the first aspect to the use of aurintricarboxylic acids, derivatives, oligo- or polymers or salts, for inhibiting adherence and colonisation of microorganisms, like bacteria, on surfaces, in particular for use in mammals. That is, it has been recognized that aurintricarboxylic acids and derivatives thereof are suitable for inhibiting adherence and colonisation of mucosa, in particular, nasal mucosa.
|Mitochondria-targeted antioxidants for treatment of age-related brain disorders|
A method for providing to a mammal a neuroprotective effect against a brain pathology that is associated with reactive oxygen species originating from mitochondria (mros). The method includes the step of administering to the mammal an skq mitochondria-targeted antioxidant in an amount effective to provide said neuroprotective effect.
|Angiogenic active lytic peptides|
This invention relates to novel synthetic lytic peptide fragments of full-length peptides with the capacity to modulate angiogenic activity in mammals. The invention also relates to the use of such peptides in pharmaceutical compositions and in methods for treating diseases or disorders that are associated with angiogenic activity..
|Honeybee repellents and uses thereof|
The present specification discloses honeybee repellents exhibiting repellent properties similar to 2-heptanone, compositions comprising such repellents, uses to repel a honeybee from a mammal, location, plant, structure treated of such repellents, and methods of treating a mammal, location, plant, structure by applying such repellents.. .
|Honeybee repellents and uses thereof|
The present specification discloses honeybee repellents exhibiting repellent properties similar to 2-heptanone, compositions comprising such repellents, uses to repel a honeybee from a mammal, location, plant, structure treated of such repellents, and methods of treating a mammal, location, plant, structure by applying such repellents.. .
|Compositions for cell culture and methods of using the same|
Supplementation of the bioflavonoids such as epigallocatechin gallate, rutin, naringin, or genistein into mammalian cell culture media are shown to be effective in reduction of acidic species variants on recombinant antibodies. The demonstrated reduction in acidic species through the use of bioflavonoids, facilitates the manufacturing of a less heterogeneous product with potential improvements in antibody structure and function..
|Antimicrobial solutions containing dichloride monoxide and methods of making and using the same|
Methods and products are provided for treating a wound or infection in a mammal or disinfecting a surface with a hypochlorous acid solution that has been activated by a catalyst. Additionally provided is a process for preparing an antimicrobial product that produces an activated hypochlorous acid solution for use as an antimicrobial..
|Drug delivery systems and use thereof|
The invention provides a microsphere formulation for the sustained delivery of an aptamer, for example, an anti-vascular endothelial growth factor aptamer, to a preselected locus in a mammal, such as the eye. In addition, the invention provides methods for making such formulations, and methods of using such formulations to deliver an aptamer to a preselected locus in a mammal.
|Charge triggering of self-organized nanoparticles|
The present application discloses a nanoparticle comprising compounds of the formula a-b-c(-d), wherein a designates an anchoring moiety having self-organizing properties in relation to the nanoparticle; b designates a cleavable linker; c designates an anionic moiety having a net charge of at least −2 at ph 6.0; and d, which is optional, designates a polymer moiety which induces long circulating properties of the nanoparticle in mammalian tissue; and wherein the average net charge of the compounds is at least −1 at ph 6.0. The application also discloses the individual compounds of the formula a-b-c(-d) as well as a drug delivery system comprising the self-organized nanoparticle having included in the interior thereof one or more pharmaceutically active agents and/or diagnostically relevant species, and a method of treating a cancerous or inflammatory condition in a mammal, involving the administration of the drug delivery system to the mammal..
|Norovirus immunogens and related materials and methods|
The inventors have successfully developed a recombinant vesicular stomatitis virus which expresses the major capsid protein of human norovirus. Infection of mammalian cells with the recombinant vesicular stomatitis virus resulted in production of high level of human norovirus virus-like particles.
A method of inhibiting alternative complement pathway activation in a mammal includes administering an amount of an antibody and/or fragment thereof that specifically binds to an epitope of the n terminus end of properdin effective to the inhibit alternative complement pathway in the subject.. .
|Making and using in vitro-synthesized ssrna for introducing into mammalian cells to induce a biological or biochemical effect|
The present invention relates to compositions, kits and methods for making and using rna compositions comprising in vitro-synthesized ssrna inducing a biological or biochemical effect in a mammalian cell or organism into which the rna composition is repeatedly or continuously introduced. In certain embodiments, the invention provides compositions and methods for changing the state of differentiation or phenotype of a human or other vertebrate cell.
|Cell-based therapy for the pulmonary system|
Cell based therapy comprises administration to the lung by injection into the blood system of viable, mammalian cells effective for alleviating or inhibiting pulmonary disorders. The cells may express a therapeutic transgene or the cells may be therapeutic in their own right by inducing regenerative effects..
|4-amino-4-oxobutanoyl peptides as inhibitors of viral replication|
The variables r1-r9, r16, r18, r19, n, m, n, m, and z are defined herein. Certain compounds of formula i are useful as antiviral agents.
|Methods and compositions for treating and preventing viral infections|
A method of treating or preventing a systemic viral infection in a mammal by administering a pharmaceutically acceptable composition selected from the group consisting of squalamine, an active isomer thereof, and an active analogue thereof, via a dosing regimen that delivers effective antiviral concentrations of squalamine. Also compositions for achieving the systemic antiviral effect..
|Antibodies reactive with b7-h3 and uses thereof|
The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human b7-h3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized b7-h3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers..
|Wirelessly-powered illumination of biological tissue|
In exemplary implementations of this invention, an implant device is wholly or partially implanted in a mammal. The implant device includes an antenna, circuitry, a supercapacitor, one or more light sources, and an array of optical fibers or light guides.
|Transcutaneous electrical nerve stimulation and method using same|
The present disclosure relates to an apparatus and associated methods to produce analgesia in a mammal by providing an electrical nerve stimulus utilizing a pulsed input of low level electrical current, wherein the level of current is measurable with the measurements utilized to at least adjust the strength of the current according to selected parameters. Additionally, the use of magnets to produce a magnetic field to further control chronic and acute pain.
|Targeted optogenetic neuromodulation for treatment of clinical conditions|
Disclosed are methods and systems and methods for methods for neuromodulation of deep-brain and other neural targets in mammals using optogenetics to treat clinical conditions or achievement of a physiological state. The neuromodulation can produce acute or long-term effects.
|Imaging probe with combined ultrasound and optical means of imaging|
The present invention provides an imaging probe for imaging mammalian tissues and structures using high resolution imaging, including high frequency ultrasound and optical coherence tomography. The imaging probes structures using high resolution imaging use combined high frequency ultrasound (ivus) and optical imaging methods such as optical coherence tomography (oct) and to accurate co-registering of images obtained from ultrasound image signals and optical image signals during scanning a region of interest..
|Amide compounds, compositions and uses thereof|
Where a, b, w, x′, l, r1, r3, r4b, and m′ are as defined herein. Provided compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, pain, inflammation, cognitive disorders, anxiety, depression, and others..
|Chemotherapeutic compositions and methods for treating human gliomas|
Disclosed are compound for targeting chemotherapeutic agents to mammalian mitochondria. Also disclosed are monoamine oxidase-specific compositions, and methods of using them for the selective therapy of mammalian cancers, and in particular, in the treatment of human gliomas.
|Methods and compositions for the delivery of a therapeutic agent|
The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration.
|Methods for preserving photoreceptor cell viability following retinal detachment|
Provided are methods for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a hydrophilic bile acid (e.g., udca or tudca) to a mammal having an eye with a detached retina.
|Compounds and methods for the prevention and treatment of tumor metastasis and tumorigenesis|
The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (i), wherein r1, r2, r3, and r4 are as defined herein, that are useful in treating a disease or disorder associated with increased prevalence of the perinucleolar compartment, such as cancer. Also disclosed is a composition containing a pharmaceutically acceptable carrier and at least one compound embodying the principles of the invention, and a method of treating or preventing cancer in a mammal..
|Ultra-concentrated rapid-acting insulin analogue formulations|
A pharmaceutical formulation comprises insulin having a variant insulin b-chain polypeptide containing an ortho-monofluoro-phenylalanine substitution at position b24 in combination with a substitution of an amino acid containing an acidic side chain at position b10, allowing the insulin to be present at a concentration of between 0.6 mm and 3.0 mm. The formulation may optionally be devoid of zinc.
|Systems and methods for enhancing cognition|
The disclosure is directed to cognitive training exercise adapted to train working memory systems in mammals in an intuitive, engaging, and adaptively challenging way to enhance cognition. Exercises engage users in the task of first seeing a grid with angled “bumpers” placed in various places throughout the grid.
|Method for biomarker and drug-target discovery for prostate cancer diagnosis and treatment as well as biomarker assays determined therewith|
The invention relates to a method for the determination of a cancer diagnostic/therapeutic biomarker assay and drug-targets including the following steps: (a) identification of potential candidate protein/peptide biomarkers and drug-targets based on the measurement of protein/peptide constituent concentrations in tissue sample proteomes as well as serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and qualitatively selecting as potential candidate protein/peptide biomarkers those which show a pronounced differential behaviour between healthy and cancerous sample proteomes; (b) optional verification of the potential candidate protein/peptide biomarkers as identified in step (a) by quantitative mass spectrometric measurement of the potential candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy non-human mammalian individuals as well as from cancerous non-human mammalian individuals and selecting as candidate protein/peptide biomarkers those which show a mass-spectrometrically measurable quantitative differential behaviour between healthy and cancerous sample proteomes; (c) validation of the candidate protein/peptide biomarkers as identified in step (a), or as optionally verified in step (b), by mass spectrometric measurement and/or antibody-based assays such as an enzyme-linked immunosorbent assay (elisa) determination of the candidate protein biomarkers in serum, plasma or any other derivatives of blood, or blood itself sample proteomes derived from healthy human individuals as well as from cancerous human individuals and selecting as protein/peptide biomarkers those which show a mass-spectrometrically measurable and/or antibody-based assay detectable differential behaviour between healthy and cancerous sample proteomes; (d) application of statistical methods to uncover single or groups of protein/peptide biomarkers as validated in step (c) as signatures for the detection of patients with cancer. The invention furthermore relates to specific biomarker assays for the highly reliable diagnosis of cancer, specifically of localized or non-localized prostate cancer, using human serum, plasma or any other derivatives of blood, or blood itself..
|Markers for preeclampsia|
This document provides methods and materials related to determining whether or not a pregnant mammal (e.g., a pregnant human) has preeclampsia. For example, methods and materials related to the use of urinary podocytes to determine whether or not a pregnant human has preeclampsia are provided..
|Bixa orellana composition for treating macular degeneration|
A composition includes an extract of seeds of bixa orellana for the photoprotection of the retinal pigment epithelium in mammals. The use of such a composition for the treatment of macular degeneration related to age (amd) in mammals is also described..
|Sustained-release formulations of topiramate|
Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile.
A method for treating an rheumatoid arthritis in a mammalian subject in need of same wherein the method comprises: administering to the mammalian subject an agent capable of modulating a ganglioside gm-1 associated activity in an amount effective to treat the disease.. .
|Vaccine candidates against johne's disease|
A composition and method for immunizing a mammal infected with mycobacterium are disclosed. The genes gcpe, psta, kdpc, papa2, impa, umaa1, fabg2_2, aceab, mbth2, lpqp, map0834c, cspb, lipn, and map1634 of m.
|Dna vaccines against tumor growth and methods of use thereof|
A dna vaccine suitable for eliciting an immune response against cancer cells comprises a dna construct operably encoding a cancer-associated inhibitor of apoptosis-family protein and an immunoactive gene product, such as a cytokine or a ligand for a natural killer cell surface receptor, in a pharmaceutically acceptable carrier. A preferred cytokine is ccl21.
|Pharmaceutical composition for the treatment of type-1 diabetes|
A composition for the prevention or treatment of type i diabetes in a subject, said composition comprising a gabaergic and incretin exemplified by gaba and glp-1/ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of t1d in mammals..
|Antibody producing non-human mammals|
Described are transgenic, non-human animals comprising a nucleic acid encoding an immunoglobulin light chain, whereby the immunoglobulin light chain is human, human-like, or humanized. The nucleic acid is provided with a means that renders it resistant to dna rearrangements and/or somatic hypermutations.
|Non invasive neuromodulation device for enabling recovery of motor, sensory, autonomic, sexual, vasomotor and cognitive function|
In one example embodiment, a neuromodulation system for inducing locomotor activity in a mammal, in cooperation with a signal generator and an electrode, delivers a signal with an overlapping high frequency pulse to a mammal. .
|Hepatitis b virus vaccines|
This document provides methods and materials for producing immune responses against hepatitis b viruses. For example, polypeptides, nucleic acid molecules encoding such polypeptides, virus-like particles containing such polypeptides, vaccine preparations containing one or more polypeptides provided herein, vaccine preparations containing one or more nucleic acid molecules provided herein, vaccine preparations containing one or more virus-like particles provided herein, and methods for inducing immune responses against hepatitis b viruses within mammals (e.g., humans) are provided..
|Compositions for improved oxidative status in companion animals|
A food composition that is useful for increasing antioxidant levels in the body is provided having increased levels of sulfur-containing amino acids, such as methionine, cysteine, or mixtures thereof. Methods of using these compositions for increasing antioxidant levels in the body in mammals, especially in companion animals, are also provided..
|Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells|
Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy..
|Isoxazole treatments for diabetes|
The present invention relates to compounds and methods for inducing synthesis and secretion of insulin from pancreatic beta cells. The methods may take place in vitro, ex vivo such as in isolates from adult mammalian tissue, or in vivo.
|Stimuli responsive adhesive gel for removal of foreign particles from soft tissue|
The present inventions are directed to novel aqueous compositions comprising a copolymer having water-soluble units and pendant catechols, said composition adapted for use on mammalian tissue and having a lower critical solubility temperature (lcst) of less than a physiological temperature, and their use, for example, in removing foreign particles from tissue surfaces, including ocular surfaces.. .
|Substituted amide compounds|
The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as ldl-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of ldl-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.. .
|Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities|
Which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-fms (csf-1r), c-kit, and/or pdgfr kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-fms, c-kit, or pdgfr kinases..
|Anti-cancer compounds targeting ral gtpases and methods of using the same|
The invention provides methods of inhibiting the growth or metastasis of a cancer in a mammal by inhibiting a ral gtpase in the mammal. The invention also provides small molecule inhibitors of ral gtpases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds of the invention, and methods of using the same..
|Composition comprising a glucocorticoid and a thiazolidinedione for inducing compelte adipogenic differentiation of mammalian stem cells|
The present invention relates to the provision of a composition comprising a glucocorticoid and a thiazolidinedione for inducing adipogenic differentiation, thereby successfully generating functional stem cells, from non-differentiated embryonic or adult stem cells originating from humans or other mammals, special preference being given to human mesenchymal stem cells. The preferred glucocorticoid is dexamethasone and the preferred thiazolidinedione is rosiglitazone.
|Compounds and compositions for use in the prevention and treatment of inflammation-related disorders, pain and fever, skin disorders, cancer and precancerous conditions thereof|
The present invention provides novel compounds and pharmaceutical compositions for the prevention and/or treatment of cancer and precancerous conditions thereof, for the treatment of pain and fever, for the treatment of skin disorders, and for treating and/or preventing inflammation-related diseases and/or cardiovascular diseases. The compounds of the invention also have analgesic properties and anti-platelet properties.
|Use of an active biological substance in abnormal cellular and viral membrane physiologies|
An active biological substance is disclosed for use in abnormal cellular and viral membrane physiologies in human and mammal organisms. The active substance has diagnostic and/or therapeutic properties and contains or consists of at least one component selected from the group of substances including: histones, covalently modified histones, histone-like polypeptides, biologically active histone sequences and histone-like polypeptides as agents for stopping the supply to solid tumours over their blood vessels, for killing cells infected by virus and for killing tumour cells with disturbed lipid asymmetry..
|Treatment and prevention of bone loss using resolvins|
The invention provides new methods for inducing or promoting bone growth and/or for reducing or preventing bone deterioration in a mammal subject. The inventive methods generally comprise administering to the subject an effective amount of a resolving.
|Locally released growth factors to mediate motor recovery after stroke|
Methods of improving recovery of a mammal after an ischemic event (e.g., stroke) are provided. In various embodiments the methods involve administering a neural growth factor (e.g., bdnf) into the infarct (e.g., stroke) cavity in a biocompatible hydrogel formulation.
|Detection, isolation and analysis of rare cells in biological fluids|
The invention provides a method for isolating or enriching a rare cell from a biological fluid of a mammal employing an antibody that binds a cell-surface antigen of the rare cell. The immobilized antibody is incubated with a sample of biological fluid that includes the rare cells and a plurality of other cells so as to form an antibody-rare cell complex.
|Mixed population of cells deriving from adipose tissue and methods of isolating and using the same|
Adipose tissue-derived stromal cells and methods of isolating and using the same. In at least one embodiment of isolated adipose tissue-derived stromal cells of the present disclosure, the cells are isolated by performing adipose tissue resection or suction on a mammalian patient, dissecting tissue obtained from said tissue resection or suction and dissociating said tissue into a cell suspension, removing adipocytes from the cell suspension, culturing the adipocyte-depleted cell suspension in egm-2-mv media, and isolating adipose tissue-derived stromal cells secreting vascular endothelial growth factor (vegf), hepatocyte growth factor (hgf), and granulocyte-colony stimulating factor (g-csf)..
|Cd40l expressing mammalian cells and their use|
Herein is reported a co-cultivation system for co-cultivating a pool of rabbit b-cells or single deposited rabbit b-cells wherein cells cd40l expressing cho cells are used as feeder in the presence of il-2 and il-21.. .
|Microfluidic chamber assembly for mastitis assay|
The present invention relates to a device and method for the detection of mastitis or other disease from a body fluid of a mammal for example from cow's milk. The device and method relates to a wedge microfluidic chamber for using a minimal amount of fluid and being able to use the device to observe leukocytes in a mono-layer for the purpose of disease detection, cell counts or the like..